Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

XDx: Funds raised in a recent $26.5 mil. Series D financing, led by Duff, Ackerman & Goodrich, will be used to expand sales and marketing for XDx' AlloMap molecular expression testing technology. The non-invasive test measures gene expression in a patient's blood to prevent physicians from transplanting organs that are genetically incompatible to their recipient. XDx launched the test for use in assessing a heart transplant patient's risk of rejection in January 2005 (1"The Gray Sheet" Jan. 3, 2005, p. 17). A portion of the funds also will support the development of a lung-transplant rejection test, expected to launch in the first half of 2007, as well as an autoimmune indication for its molecular diagnostic. The San Francisco, Calif.-based firm is looking to partner with a pharmaceutical or biotech company, according to CFO Vikram Jog. XDx' technology would be used to identify biomarkers for drug development...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT023213

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel